Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline

Group 1 - Edgewise Therapeutics, Inc. (EWTX) is recognized as a promising investment opportunity, particularly highlighted by JPMorgan's increased price target from $34 to $45, maintaining an Overweight rating [2] - The company is focused on developing precision therapies for serious muscle disorders, including Duchenne and Becker muscular dystrophies, with a robust pipeline of small-molecule drug candidates [5] - Anticipation is building for the full 12-week data on EDG-7500 expected in Q2, which could significantly impact the company's fundamental outlook [2] Group 2 - Long-term results from the MESA study indicate that patients on sevasemten maintained stable functional abilities over 3.5 years, contrasting with expected declines in Becker muscular dystrophy [3] - Continued follow-ups from prior assessments confirmed sustained stabilization and a favorable safety profile for sevasemten, with top-line data from the GRAND CANYON pivotal cohort expected in Q4 [4] - The overall setup for EWTX in 2026 is viewed as increasingly favorable, reflecting confidence in the company's potential and pipeline developments [2]